'Update on merger'
As filed · Suven Pharmaceuticals Limited has informed the Exchange regarding 'Update on merger'.
What happened
FactSuven Pharmaceuticals Limited has informed the Exchange regarding 'Update on merger'. Law Company Tribunal, Mumbai Bench (the “NCLT”), inter alia, directing the convening of the meetings. In the above context, we are pleased to inform that the NCLT, vide its order pronounced on March 27, 2025 (as.
Why it matters
CapitSignal interpretationOnce an insolvency process is admitted, control of the company passes from the board to a resolution professional and equity ranks last in any recovery.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
WithdrawnOur medium-term objective is to qualify approximately two new products each year, combining opportunities with the existing anchor customer and new customer across Europe and Japan.
The photochromic portfolio remained balanced, supported by our established chemistry platforms and customer relationships.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Admission or rejection of the application by the tribunal
- Appointment of a resolution professional
- Claims admitted against the company
- Our vision of a US$1 billion business by 2030 remains there. We are committed to reach there. (management committed by FY30)
- our vision for US$1 billion by 2030. (management committed by FY30)
Evidence
- Suven Pharmaceuticals Limited has informed the Exchange regarding 'Update on merger'.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- INSOLVENCY base 93; +5 quantified amount; explicit insolvency/default evidence present; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%